Latest Commercialization News

Advanced Health Intelligence has appointed Dylan Garnett as its new CEO, signaling a strategic pivot towards commercialisation and revenue growth. Garnett’s extensive background in healthcare, insurance, and digital health positions AHI for its next growth phase.

Cobalt Blue Holdings has secured a crucial works approval for its Kwinana Cobalt Refinery, pushing Australia’s first dedicated cobalt processing plant closer to a final investment decision by the end of 2025.

Codeifai Limited has mutually terminated its acquisition of Trust Codes, redirecting focus to its upcoming QuantumAI Secure platform acquisition and SaaS expansion.

VBX Limited reports promising low-silica bauxite discoveries at East Kalumburu A near its flagship Wuudagu project, alongside key strategic appointments and ongoing drilling programs advancing the project towards a targeted DFS completion in early 2026.

Xstate Resources has completed well pad construction for its Diona-1 well in Queensland’s Surat-Bowen Basin and is poised to begin drilling with a 51% interest in ATP 2077.

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

Medallion Metals has taken a crucial step forward by ordering a secondary ball mill to upgrade the Cosmic Boy Concentrator, underpinning its Sulphide Production Strategy and advancing its feasibility study toward a final investment decision.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

Metallium Limited and Ucore Rare Metals have entered a binding 12-month collaboration to integrate their cutting-edge technologies, aiming to establish the first fully U.S.-based rare earth element refining pathway and reduce reliance on Chinese supply chains.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Marvel Gold Limited has significantly increased its landholding in Tanzania’s Iramba-Sekenke Greenstone Belt, acquiring two new prospecting licences and applying for a third, setting the stage for a maiden drilling campaign.